ECLIPSE LIFE SCIENCES: BETTIS‑1 TRIAL MET ITS PRIMARY ENDPOINT, DEMONSTRATING FAVORABLE SAFETY PROFILE ACROSS BOTH EC-104 FORMULATIONS

Reuters · 2d ago

Please log in to view news